Article Text

Download PDFPDF

PO.4.90 Remission and clinical patterns of systemic lupus erythematosus (SLE) in southern pakistan: a retrospective cohort study
  1. Mohammad Saeed1,
  2. Aneela Pasha2,
  3. Syed Hussain Azhar Rizvi1,
  4. Maham Munawar1,
  5. Zehra Abaad Elias1,
  6. Muhammad Irfan Shafi3,
  7. Tario Gazdar1 and
  8. Maryam Pyar Ali Lakhdir2
  1. 1ImmunoCure Karachi PAKISTAN
  2. 2Department of Community Health Sciences, Aga Khan University Karachi PAKISTAN
  3. 3Department of Information Technology, BenchMatrix Pvt Ltd. Karachi PAKISTAN


Background SLE is a difVcult to treat autoimmune disease due to clinical heterogeneity, unpredictability of disease iares and limited therapeutics. These challenges are worsened in a low-middle income country (LMIC) setting, yet clinical epidemiology from LMIC may have global beneVts.

Objectives To determine (i) the clinical pattern of SLE and (ii) the effect of SLE severity and treatment regimen on time to remission.

Methods A retrospective cohort study of 200 SLE patients’ medical records (2014–20) from ImmunoCure clinic was conducted. Patients fulVlled ACR criteria 1997 for SLE classiVcation. SLEDAI-2K categories were used as outcome measure: mild (score <=6), moderate (7–10), severe (>10) to evaluate clinical pattern of SLE. Statistical analyses were performed using STATA v16.0. Kruskal-Wallis test was used for continuous measures, and Pearson’s chi square test was used to compare categorical variables across SLEDAI severity. Remission status based on DORIS criteria and time to remission (>1year; n=94) was the secondary outcome.

Total doses of all drugs were calculated. Survival regression performed with Kaplan Meier curve.

Results Most frequent antibodies are anti-dsDNA (63%), SSA (24%) and Ku (17.5%). Anti-cardiolipin (aCL) antibodies associate with severe SLE (OR = 3.6, P<0.01). Most common presentations were arthritis (85%), alopecia (53%), anemia (38%), rash (35%) and CNS disease (28%). Nephritis, CNS disease, cytopenias and oral ulcers are signiVcantly associated with severe SLE (P<0.01). ILD is in 10% of our cohort. Frequency of severe SLE was 47.5%, whereas mild disease was 16.5%. Mean duration of follow up was 41±19 months.

Every month of follow-up increased the odds of remission by 6% (P<0.05). Clinical remission on treatment (at Pred<=5mg) was successfully achieved in 62% patients. Complete remission (off all drugs & Pred) was achieved in 24 patients (14 in severe SLEDAI category) out of 200, with a mean post remission follow-up of 18 ± 15 months.. Hazard of time to remission is 61% (CI: 0.21–0.77, P=0.01) less in severe SLE as compared to mild SLE disease activity (Figure 1).

Conclusion Sustained remission is possible even in severe SLE in a LMIC setting if adequate immunosuppression is provided with persistent clinical follow-up.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.